ARS Pharmaceuticals, Inc.
SPRY
$15.80
-$0.11-0.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.65M | 8.00M | -49.10M | -44.84M | -49.70M |
| Total Depreciation and Amortization | 348.00K | 79.00K | 62.00K | 62.00K | 64.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.28M | 7.28M | 5.11M | 4.40M | 3.28M |
| Change in Net Operating Assets | -14.46M | -1.81M | -1.93M | -3.77M | -7.20M |
| Cash from Operations | -20.48M | 13.55M | -45.86M | -44.16M | -53.55M |
| Capital Expenditure | -571.00K | -563.00K | -170.00K | -73.00K | -65.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -67.95M | -105.54M | 21.87M | -41.69M | 15.92M |
| Cash from Investing | -68.52M | -106.10M | 21.70M | -41.76M | 15.85M |
| Total Debt Issued | 69.38M | 69.38M | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.48M | 3.02M | 3.29M | 3.53M | 5.84M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 72.87M | 72.40M | 3.29M | 3.53M | 5.84M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.14M | -20.15M | -20.88M | -82.39M | -31.86M |